Elevance Health (ELV), a prevalent name amid the bio-tech market panorama, is presently under scrutiny due to pertinent financial and legal grounded issues. Investors are poised with an opportunity to spearhead the Securities Fraud lawsuit against the organization. Despite Mendicaid related issues causing the stock to plummet, various analysts such as RBC Capital and Wells Fargo have reiterated their bullish standing on ELV, maintaining their 'Buy' and 'Outperform' ratings respectively. Financial stalwarts, such as Barclays, have altered their price target for ELV due to the underlying Medicare concerns. Moreover, ELV insiders have liquidated shares worth US$6.9m, hinting towards potential weaknesses, while Cantor Fitzgerald remains resolute with their 'Overweight' rating on Elevance Health. Amid this financial turmoil, shareholders have approved Anthem's rebranding as Elevance Health.
Elevance Health ELV News Analytics from Thu, 19 May 2022 07:00:00 GMT to Fri, 06 Jun 2025 21:07:50 GMT -
Rating -7
- Innovation 1
- Information 3
- Rumor -5
